Recent

% | $
Quotes you view appear here for quick access.

CryoLife Inc. Message Board

  • dlhild@ymail.com dlhild May 14, 2010 7:07 PM Flag

    Annual Meeting Questions:

    1. For 2009, what was the "net cash flow", after allocating all related fixed costs, generated from the sale of all "tissue" related products?

    2. For 2009, what was the "net cash flow", after allocating all related fixed costs, generated from the sale of "BioGlue"?

    3. For 2009, what was the "net cash flow", after allocating all related fixed costs, generated from the sale of "HemoStase"?

    4. What "due diligence" did CryoLife do prior to acquiring 2.3 million shares of Medafor stock? Specifically address how the CryoLife board determined that they had done sufficient "due diligence" to warrant the expenditure of $4.6 million to acquire an illiquid investment in an unfriendly company?

    5. For 2009, what was the total amount of HemoStase sales in Europe generally? In Germany specifically?

    6. For calendar years 2011 thru 2013 (next 3 calendar years), what is CryoLife's sales projection for BioGlue?

    7. Assuming no disruption of HemoStase product, what is CryoLife projection for HemoStase sales for the next two yreas, calendar years 2010 and 2011?

    8. During the next 3 years, what new products does CryoLife expect to bring to the market place? Also, what are the annual sales projections for these new products?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If you read quaterly report, you might have already gotten your anwsers of some of these question.

      I will post it from my previous post which was pasted from quaterly report.. hey i learned something fro
      ""Cardiac revenues for the first quarter 2010 increased to 23% compared to the corresponding period of 2009. The increase in first quarter compared to the prior year is primarily due to a 21% increase in cardiac tissue unit shipments. We believe that this is in large part due to the efforts of our cardiac specialist sales force.

      Additionally, we're seeing growing interest in international markets for our preserved cardiac tissues. The vascular business continues to be very well driven by strong unit growth. Vascular revenues for the first quarter of 2010 increased to 10% compared to the corresponding period in 2009. This increase primarily resulted from an 8% increase in unit shipments for the first quarter of 2010 compared to the comparable period of 2009. "" m you....never get tired making your point...haha

 
CRY
11.13-0.01(-0.09%)May 22 4:02 PMEDT